| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Prime Medicine, Inc.: Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates | 943 | GlobeNewswire (Europe) | -- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for... ► Artikel lesen | |
| Di | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation | 696 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
03-March-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| Di | Rüstungs-Rallye nach Iran-Angriff: Rheinmetall, DroneShield und Harvest Technology im Fokus der Anleger | Small- & Micro Cap Investment | |||
| Di | Paradigmenwechsel in der onkologischen Dermatologie: Vidac Pharma als Innovator, was machen Almirall und Biofrontera? | 608 | inv3st.de | Die onkologische Dermatologie steht an der Schwelle zu einer Revolution, die das bisherige Verständnis der Krebsbehandlung grundlegend verändern könnte. Der globale Markt für die Behandlung der Aktinischen... ► Artikel lesen | |
| Di | CalciMedica, Inc.: CalciMedica Reports 2025 Financial Results and Provides Clinical Updates | 570 | PR Newswire | Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related... ► Artikel lesen | |
| Di | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 | 547 | GlobeNewswire (Europe) | STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| Di | Press Release: Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update | 476 | Dow Jones News | Press Release: Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
-- Significant achievements in 2025, enabling multiple near-term clinical
milestones across... ► Artikel lesen | |
| Di | Arcutis Biotherapeutics, Inc.: Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis | 462 | GlobeNewswire (Europe) | Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein... ► Artikel lesen | |
| Di | PTA-News: Vidac Pharma Holding PLC: Vidac Pharma präsentiert Fall von "Compassionate Use" bei pädiatrischem Hirntumor auf dem Eilat-Symposium über pädiatrischen Krebs | 342 | Dow Jones News | DJ PTA-News: Vidac Pharma Holding PLC: Vidac Pharma präsentiert Fall von "Compassionate Use" bei pädiatrischem Hirntumor auf dem Eilat-Symposium über pädiatrischen Krebs
Unternehmensmitteilung... ► Artikel lesen | |
| Di | Moderna, Inc.: Moderna Resolves Global Patent Litigation with Arbutus/Genevant | 312 | ACCESS Newswire | Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal Circuit... ► Artikel lesen | |
| Di | Vidac Pharma präsentiert Fall von "Compassionate Use" bei pädiatrischem Hirntumor auf dem Eilat-Symposium über pädiatrischen Krebs | 288 | IR-WORLD | London, UK, 3. März 2026 - Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ)
gibt bekannt, dass das Unternehmen auf dem Eilat-Symposium über pädiatrischen Krebs Ergebnisse... ► Artikel lesen | |
| Di | Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus | 275 | AFX News | WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary... ► Artikel lesen | |
| Di | EQS-Media: REPLOID Group AG: Feierliche Eröffnung der ersten landwirtschaftlichen ReFarmUnit | 258 | EQS Group (DE) | EQS-Media / 03.03.2026 / 14:19 CET/CEST
PRESSEMITTEILUNG
REPLOID Group AG: Feierliche Eröffnung der ersten landwirtschaftlichen ReFarmUnit
Wels, 3. März 2026 - Gestern fand die feierliche... ► Artikel lesen | |
| Di | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in March | 252 | EQS Group (EN) | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in March
03.03.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| Di | OSE Immunotherapeutics - Reaffirmed dedication to core assets | 212 | Edison Investment Research | OSE Immunotherapeutics has reaffirmed its strategy of streamlining its clinical pipeline following some developments to its partnered assets. For ABBV-230 (OSE-230), partnered with AbbVie, OSE had previously... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 50,20 | 2,47 | +4,92 % | 2,25 | 23.03.2026 | |
| CSL | 88,15 | 2,59 | +2,94 % | 1,84 | 10.03.2026 | |
| AMGEN | 324,80 | 8,12 | +2,50 % | 2,52 | 13.02.2026 | |
| NOVONESIS | 49,690 | 0,87 | +1,75 % | 4,25 | 20.03.2026 | |
| GENUS | 33,000 | 0,38 | +1,15 % | 0,11 | 05.03.2026 | |
| STRYKER | 330,70 | 2,94 | +0,89 % | 0,88 | 31.03.2026 | |
| BIO-TECHNE | 47,800 | 0,27 | +0,56 % | 0,08 | 13.02.2026 | |
| BRUKER | 32,670 | 0,17 | +0,52 % | 0,05 | 23.03.2026 | |
| REGENERON PHARMACEUTICALS | 663,60 | 3,02 | +0,46 % | 0,94 | 20.02.2026 | |
| SARTORIUS STEDIM BIOTECH | 168,85 | 0,69 | +0,41 % | 0,69 | 31.03.2026 |